Epidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma

European Urology, Supplements

Volumn 11, Issue 3, 2012, Pages 52-59

  Protzel, Chris ^a   Maruschke, Matthias ^a   Hakenberg, Oliver W ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Etiology; Folliculin; Hypermethylation; Renal cancer; VHL gene

Indexed keywords

ESTRONE; FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PESTICIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; TRICHLOROETHYLENE; VASCULOTROPIN; VITAMIN D RECEPTOR; VON HIPPEL LINDAU PROTEIN;

BIRT HOGG DUBE SYNDROME; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CARCINOGENESIS; CELL CYCLE REGULATION; CIGARETTE SMOKING; CLEAR CELL CARCINOMA; DEMOGRAPHY; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EUROPE; GENE MUTATION; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HERITABILITY; HISTONE MODIFICATION; HUMAN; KIDNEY CARCINOMA; LEIOMYOMATOSIS; NUTRITION; OBESITY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

EID: 84862866431     PISSN: 15699056     EISSN: 18781500     Source Type: Journal    
DOI: 10.1016/j.eursup.2012.05.002     Document Type: Review

References (72)

1. Amin M.B., Tamboli P., Javidan J., et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002, 26:281-291.
2. Algaba F., Akaza H., López-Beltrán A., et al. Current pathology keys of renal cell carcinoma. Eur Urol 2011, 60:634-643.
3. Waldert M., Klatte T., Haitel A., et al. Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol 2010, 57:661-666.
4. Sukov W.R., Lohse C.M., Leibovich B.C., Thompson R.H., Cheville J.C. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol 2012, 187:54-59.
5. Moch H., Gasser T., Amin M.B., Torhorst J., Sauter G., Mihatsch M.J. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000, 89:604-614.
6. Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
7. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
8. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008, 127:2893-2917.
9. Nepple K.G., Yang L., Grubb R.L., Strope S.A. Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006. J Urol 2012, 187:32-38.
10. Lungberg B.C., Campbell S.C., Choi H.Y., et al. Etiology and epidemiology. Kidney cancer 2011, International Consultation on Urological Diseases-European Association of Urology, Paris, France. Z. Kirkali, P. Mulders (Eds.).
11. Pichler M, Hutterer GC, Chromecki TF, et al. Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5- and 10-year metastasis-free survival. Int Urol Nephrol. In press. doi:10.1007/s.11255-012-0165-5.
12. Palsdottir H.B., Hardarson S., Petursdottir V., et al. Incidental detection of renal cell carcinoma is an independent prognostic marker: results of a long-term, whole population study. J Urol 2012, 187:48-53.
13. Chow W.H., Linehan W.M., Devesa S.S. Re: Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2007, 99:569-570. author reply 570-1.
14. Karakiewicz P.I., Trinh Q.-D., Bhojani N., et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007, 51:1616-1624.
15. Mason R.J., Abdolell M., Trottier G., et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 2011, 59:863-867.
16. Pascual D., Borque A. Epidemiology of kidney cancer. Adv Urol 2008, 782381.
17. Athar U., Gentile T.C. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 2008, 15:3954-3966.
18. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
19. Levi F., Ferlay J., Galeone C., et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008, 101:949-958.
20. Mandel J.S., McLaughlin J.K., Schlehofer B., et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995, 61:601-605.
21. Boffetta P., Dosemeci M., Gridley G., Bath H., Moradi T., Silverman D. Occupational exposure to diesel engine emissions and risk of cancer in Swedish men and women. Cancer Causes Control 2001, 12:365-374.
22. Boffetta P., Burstyn I., Partanen T., et al. Cancer mortality among European asphalt workers: an international epidemiological study. II. Exposure to bitumen fume and other agents. Am J Ind Med 2003, 43:28-39.
23. Bruning T., Pesch B., Wiesenhutter B., et al. Renal cell cancer risk and occupational exposure to trichloroethylene: results of a consecutive case-control study in Arnsberg, Germany. Am J Ind Med 2003, 43:274-285.
24. Mundt K.A., Birk T., Burch M.T. Critical review of the epidemiological literature on occupational exposure to perchloroethylene and cancer. Int Arch Occup Environ Health 2003, 76:473-491.
25. Karami S., Boffetta P., Rothman N., et al. Renal cell carcinoma, occupational pesticide exposure and modification by glutathione S-transferase polymorphisms. Carcinogenesis 2008, 29:1567-1571.
26. Chow W.H., Devesa S.S., Warren J.L., Fraumeni J.F. Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628-1631.
27. Lee J.E., Spiegelman D., Hunter D.J., et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst 2008, 100:1695-1706.
28. Karami S., Brennan P., Rosenberg P.S., et al. Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One 2009, 4:e7013.
29. Grieb S.M., Theis R.P., Burr D., Benardot D., Siddiqui T., Asal N.R. Food groups and renal cell carcinoma: results from a case-control study. J Am Diet Assoc 2009, 109:656-667.
30. Weikert S., Boeing H., Pischon T., et al. Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2006, 118:3133-3139.
31. George S.M., Park Y., Leitzmann M.F., et al. Fruit and vegetable intake and risk of cancer: a prospective cohort study. Am J Clin Nutr 2009, 89:347-353.
32. Verine J., Pluvinage A., Bousquet G., et al. Hereditary renal cancer syndromes: an update of a systematic review. Eur Urol 2010, 58:701-710.
33. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
34. Mena A.C., Pulido E.G., Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010, 21(Suppl 1):S3-S11.
35. Banks R.E., Tirukonda P., Taylor C., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006, 66:2000-2011.
36. Finley D.S., Pantuck A.J., Belldegrun A.S. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011, 16(Suppl 2):4-13.
37. Pfaffenroth E.C., Linehan W.M. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 2008, 8:779-790.
38. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
39. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343-2350.
40. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993, 62:89-124.
41. Pollard P.J., Briere J.J., Alam N.A., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005, 14:2231-2239.
42. Coleman J.A. Familial and hereditary renal cancer syndromes. Urol Clin North Am 2008, 35:563-572. v.
43. Linehan W.M. Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol 2009, 27:3731-3733.
44. Schmidt L.S., Warren M.B., Nickerson M.L., et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001, 69:876-882.
45. Baba M., Hong S.B., Sharma N., et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006, 103:15552-15557.
46. Chen J., Futami K., Petillo D., et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One 2008, 3:e3581.
47. Hartman T.R., Nicolas E., Klein-Szanto A., et al. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene 2009, 28:1594-1604.
48. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
49. Baldo P., Cecco S., Giacomin E., Lazzarini R., Ros B., Marastoni S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 2008, 8:647-665.
50. Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16:525-537.
51. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
52. Hadoux J., Vignot S., De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 2010, 4:143-154.
53. Arai E., Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 2011, 4:58-73.
54. Hino O. Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med 2004, 4:807-811.
55. Dalgliesh G.L., Furge K., Greenman C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
56. Arai E., Ushijima S., Tsuda H., et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res 2008, 14:5531-5539.
57. Christoph F., Weikert S., Kempkensteffen C., et al. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res 2006, 12:5040-5046.
58. Urakami S., Shiina H., Enokida H., et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006, 12:6989-6997.
59. Kawamoto K., Hirata H., Kikuno N., Tanaka Y., Nakagawa M., Dahiya R. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 2008, 123:535-542.
60. Rogenhofer S., Kahl P., Mertens C., et al. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 2011, 109:459-465.
61. Ellinger J., Kahl P., Mertens C., et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 2010, 127:2360-2366.
62. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
63. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
64. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
65. Jones J., Otu H., Spentzos D., et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005, 11:5730-5739.
66. Jones J., Libermann T.A. Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res 2007, 13. 685s-92s.
67. Sultmann H., von Heydebreck A., Huber W., et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 2005, 11:646-655.
68. Maruschke M., Koczan D., Reuter D., et al. Putative biomarker genes for grading clear cell renal cell carcinoma. Urol Int 2011, 87:205-217.
69. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
70. Maruschke M., Reuter D., Koczan D., Hakenberg O.W., Thiesen H.J. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU Int 2011, 108:E29-E35.
71. Lam J.S., Leppert J.T., Figlin R.A., Belldegrun A.S. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005, 66:1-9.
72. Eichelberg C., Junker K., Ljungberg B., Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55:851-863.